Autres langues Valerio Therapeutics Deutsche Boerse AG

Actions

C4X

FR0010095596

Produits pharmaceutiques

Temps réel estimé Tradegate 13:33:07 21/09/2026			Varia. 5j.	Varia. 1 janv.
0,5780 ^EUR	+0,52 %		-13,64 %	+301,41 %

24/08	Bourse : tensions chez Volkswagen et milliards en série
24/08	Valerio Therapeutics va acquérir Etherna Immunotherapies pour 30 millions d'euros	MT

Autres langues

24/08	Valerio Therapeutics to Buy Etherna Immunotherapies in EUR30 Million Deal
24/08	Valerio Therapeutics : Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
24/08	Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
17/08	Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase
17/08	Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition
16/07	Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies
16/07	Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates
16/07	Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update
16/07	Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
16/07	Valerio Therapeutics : Announces Development Collaboration with Abivax and Provides Pipeline Update
01/07	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
01/07	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines
01/07	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.
17/06	Valerio Therapeutics Names New CEO
16/06	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
16/06	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes
16/06	Valerio Therapeutics Société Anonyme Announces CEO Changes
16/06	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
19/05	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration
18/05	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co
18/05	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company
18/05	Valerio Therapeutics Enters Binding Term-Sheet for Collaboration and Exclusive License with Stealth-Mode Biotech Company
18/05	Valerio Therapeutics : announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company
04/05	Valerio Therapeutics : Inside Information / Other news releases
04/05	Valerio Therapeutics Announces Launch of Invimmune and Provides Update on in Vivo Cell Therapy Approaches